Scancell Holdings plc (LON:SCLP – Get Free Report) shares shot up 29.8% on Monday . The company traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.14). 10,537,342 shares were traded during trading, an increase of 1,073% from the average session volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).
Scancell Price Performance
The stock has a market cap of £113.93 million, a P/E ratio of -16.86 and a beta of 0.35. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The company’s fifty day simple moving average is GBX 8.43 and its 200-day simple moving average is GBX 10.88.
Scancell (LON:SCLP – Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) EPS for the quarter. As a group, sell-side analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current year.
About Scancell
Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Featured Stories
- Five stocks we like better than Scancell
- What is a Secondary Public Offering? What Investors Need to Know
- Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
- How to Short a Stock in 5 Easy Steps
- Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
- What is a support level?
- 3 Hot New IPOs Defying the 2025 Market Slump
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
